Intraperitoneal heparin ameliorates the systemic inflammatory response in PD patients

Area of Science:

• Nephrology
• Immunology
• Pharmacology

Background:

• End-stage renal disease (ESRD) patients exhibit high cardiovascular mortality linked to chronic inflammation.
• Heparins show potential anti-inflammatory effects.
• Investigating intraperitoneal heparin's impact on inflammation in peritoneal dialysis (PD) patients is crucial.

Purpose of the Study:

• To evaluate the long-term effects of intraperitoneal tinzaparin on local and systemic inflammation in PD patients.
• To assess changes in inflammatory markers during tinzaparin treatment compared to placebo.

Main Methods:

• A double-blinded, cross-over study involving 21 PD patients with ESRD.
• Patients received either tinzaparin (4,500 anti-Xa IU) or placebo daily in dialysis bags for 3-month periods, with a 1-month wash-out.
• Blood and dialysate samples were analyzed for inflammatory markers, with dialysate marker rates adjusted for ultrafiltration variations.

Main Results:

• Intraperitoneal tinzaparin treatment led to a 25.8% reduction in plasma C-reactive protein (p = 0.032).
• Plasma fibrinogen concentration decreased by 7.3% (p = 0.042).
• Dialysate interleukin-6 appearance rate showed a significant 54.5% reduction (p = 0.007) compared to placebo.

Conclusions:

• Long-term intraperitoneal tinzaparin administration effectively reduces local and systemic inflammatory markers in ESRD patients undergoing PD.
• This treatment may offer a strategy to mitigate inflammation-associated risks in PD patients.